IBM has been selected by Torrent Pharmaceuticals for consulting services including upgrading of SAP application and hardware infrastructure. This partnership will help Torrent Pharma gear up for the next level of growth.
As part of the engagement, IBM will also help Torrent comply with International Financial Reporting Standards (IFRS), through use of Parallel Ledger functionality in New General Ledger (New GL). IBM will enhance the Disaster Recovery (DR) processes at Torrent Pharma to ensure a near-zero data loss model. In addition, the engagement will help Torrent upgrade their hardware infrastructure, in order to address the higher power usage that Torrent would need for running the new version of SAP (ECC 6.0).
Torrent is in a phase of rapid growth and was looking for a consulting partner to upgrade infrastructure. IBM was chosen after Request for Proposals (RFP) were invited and evaluated from many SAP implementers in the country.
IBM India has successfully addressed unique customer requirements in the pharmaceutical industry by leveraging its world-wide capabilities, assets, innovative approaches and experience. The company has a wide range of global assets, both from business and technology perspective, and it is able to replicate these assets for clients in India as well. It is also creating unique solutions and localizing innovation efforts to cater to specific client needs in an Indian context.
"Organizations like Torrent Pharmaceuticals, which are moving towards the next phase of internal growth, understand the significance of adopting services from experienced consultants like IBM. We have developed a portfolio of repeatable, automated services solutions for clients across a range of industries," stated Sandip Patel, Managing Partner, Global Business Services, IBM India, South Asia.
According to a recent report by Springboard Research, IBM ranked as the number one vendor in IT infrastructure services and consulting services.
Torrent Pharma, with an annual turnover of Rs 1400 crore, is the flagship company of Rs 5400 crore Torrent Group. With many of its products ranking among the top 200 brands, Torrent continues to be at the forefront of the Indian pharmaceutical industry through research, innovation and breakthrough discoveries in the therapeutics areas of diabetology, cardiovascular, central nervous system, gastro-intestinal, anti-infective and pain management.
Its state-of-the-art research centre has over 620 scientists engaged in various drug discovery and development projects. The company has two world-class manufacturing facilities at Gujarat and Himachal Pradesh which supplies its products across all its markets through an elaborate supply chain network.